aTyr Pharma (NASDAQ:ATYR) Downgraded by Jones Trading to Hold

Jones Trading lowered shares of aTyr Pharma (NASDAQ:ATYR) from a strong-buy rating to a hold rating in a report released on Monday morning,Zacks.com reports.

Several other equities research analysts have also recently commented on the company. Wells Fargo & Company reissued an “equal weight” rating on shares of aTyr Pharma in a research note on Monday. Wall Street Zen cut aTyr Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Leerink Partnrs cut aTyr Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday. Leerink Partners reissued a “market perform” rating on shares of aTyr Pharma in a research note on Monday. Finally, HC Wainwright cut aTyr Pharma from a “buy” rating to a “neutral” rating in a research note on Monday. One equities research analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, aTyr Pharma has a consensus rating of “Hold” and a consensus target price of $23.25.

aTyr Pharma Trading Up 6.4%

Shares of ATYR opened at $1.08 on Monday. The stock has a fifty day moving average price of $5.20 and a two-hundred day moving average price of $4.34. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63. aTyr Pharma has a 52-week low of $1.00 and a 52-week high of $7.29. The company has a market cap of $105.83 million, a price-to-earnings ratio of -1.35 and a beta of 1.01.

aTyr Pharma (NASDAQ:ATYR) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.04). Analysts predict that aTyr Pharma will post -0.91 EPS for the current fiscal year.

Hedge Funds Weigh In On aTyr Pharma

Institutional investors have recently modified their holdings of the business. California State Teachers Retirement System bought a new position in shares of aTyr Pharma during the 2nd quarter valued at about $28,000. Group One Trading LLC acquired a new position in shares of aTyr Pharma during the fourth quarter worth about $26,000. Ameritas Investment Partners Inc. acquired a new position in shares of aTyr Pharma during the second quarter worth about $45,000. Legal & General Group Plc acquired a new position in shares of aTyr Pharma during the second quarter worth about $49,000. Finally, Two Sigma Advisers LP acquired a new position in shares of aTyr Pharma during the fourth quarter worth about $44,000. Institutional investors own 61.72% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.